Algert Global LLC Has $5.45 Million Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Algert Global LLC increased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 40.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 725,305 shares of the biotechnology company’s stock after purchasing an additional 209,096 shares during the quarter. Algert Global LLC’s holdings in BioCryst Pharmaceuticals were worth $5,454,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BCRX. Venturi Wealth Management LLC bought a new position in BioCryst Pharmaceuticals in the fourth quarter worth approximately $46,000. R Squared Ltd bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth $48,000. KBC Group NV lifted its holdings in shares of BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 4,537 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at $80,000. Finally, Syon Capital LLC bought a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at $99,000. 85.88% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BCRX has been the subject of several recent research reports. Royal Bank of Canada restated an “outperform” rating and issued a $11.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Cantor Fitzgerald assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an “overweight” rating and a $20.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price objective on shares of BioCryst Pharmaceuticals in a report on Thursday, April 10th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.13.

BioCryst Pharmaceuticals Trading Up 23.5 %

BCRX stock opened at $11.03 on Tuesday. The stock has a market cap of $2.31 billion, a P/E ratio of -18.08 and a beta of 1.08. The stock’s fifty day simple moving average is $7.74 and its two-hundred day simple moving average is $7.83. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.75 and a 1-year high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, May 5th. The biotechnology company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.27. The company’s revenue was up 56.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.17) earnings per share. As a group, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.